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Downstaging of hepatocellular carcinoma to enable liver transplantation has become an 
area of intense interest and research.  It may allow a curative option in patients outside 
widely accepted transplantation criteria, with outcomes that, in some studies, are compa-
rable to transplantation for patients within criteria.  There have been conflicting opinions on 
the best downstaging protocols, criteria for downstaging eligibility and for assessment of 
response.  We therefore aimed to review the literature and evidence for downstaging, as 
well as considering its drawbacks.  Conclusion: Pooled analyses have suggested success 
in down staging in about half of patients treated, but with higher recurrence rates than pa-
tients initially within transplantation criteria. Studies with strict inclusion criteria and manda-
tory waiting time before transplantation reported survival equivalent to patients who did not 
require downstaging. In carefully selected patients, there is a role for down staging to pro-
vide the chance of transplantation and cure, with acceptable outcomes.  Further multi cen-
ter, well-designed studies are required to clarify who will mostly benefit. Until such data is 
available, downstaging criteria should be stated within transplantation programs and rele-
vant decisions should be discussed by multidisciplinary teams. 
  
Introduction  
Hepatocellular carcinoma (HCC) is the commonest primary liver cancer and the 5th most 
prevalent cancer in males.   Worldwide, it is the third most common cause of cancer death. 
(1).  Its incidence in the US has more than tripled since 1980 and liver cancer death rates 
have increased by almost 3% since 2000 (2).   It is an important indication for liver trans-
plantation, as the latter can remove the tumor, whist also curing the underlying liver dis-
ease.  However, more than 70% of cases present at an advanced stage and are unsuita-
ble for curative interventions (resection or transplantation) either due to tumor burden or 
poor liver function (3).  
The most commonly used staging systems for HCC include the Barcelona Clinic Liver 
Cancer (BCLC) (4) and the American Joint Committee on Cancer (AJCC) tu-
mor/node/metastasis (TNM) classification.  The United Network for Organ Sharing (UNOS) 
has incorporated the Milan criteria into T1 and T2 in a modified staging system for HCC.  
Listing criteria for transplantation include: 
1. Milan criteria (5)/UNOS T2 stage (A single tumor ≤5cm diameter or up to 3 tumors all 
≤3cm) 
2. University of California, San Francisco (UCSF) (a single lesion ≤6.5 cm in diameter or 2 
lesions ≤4.5 cm with total tumor diameter ≤8 cm) (6) 
3. Extended Milan 2009 - In the UK, NHS Blood and Transplant (NHSBT) uses these cri-
teria (A single tumor ≤5cm diameter or up to 5 tumors all ≤3cm, or a single tumor >5cm 
and ≤7cm diameter where there has been no evidence of tumor progression (volume 
increase by <20%) and no extra-hepatic spread and no new nodule formation over a 6-
month period) 
4. ’Up to 7 criteria’ 2009 (the sum of the size of the largest tumor (in cm) and the number 
of tumors ≤7). Metroticket Investigator Study Group (7) 
5. Duvoux criteria/AFP model (which takes into account largest tumor size, number of 
nodes and AFP - a score of 2 or less allows listing). (8) 
‘Downstaging’ is the process of applying locoregional therapy to tumors currently outside 
of accepted transplant criteria, with the aim of reducing tumor burden to allow transplanta-
tion.  This is used because it is recognized that there may be a large number of cases who 
may benefit from transplantation, but do not necessarily meet the stringent Milan (or other) 
criteria.  This process has raised some concerns about higher risks of recurrence when 
transplanting patients who did not originally meet listing criteria. 
In this review, we critically evaluate available data and evidence on downstaging HCC. 
 
Loco-regional therapies for downstaging hepatocellular carcinoma  
Locoregional treatments, or ‘liver-directed therapies (LDT)’ include transarterial (‘bland’) 
embolization (TAE), transarterial chemoembolization (TACE, including drug-eluting beads, 
DEB-TACE), transcatheter arterial chemoinfusion (TACI), radio frequency ablation (RFA), 
microwave ablation and percutaneous ethanol injection (PEI), as well as transarterial radio 
embolization (TARE) and stereotactic body radiation (9, 10).  Liver resection may form part 
of a multimodal down-staging strategy.  
Locoregional treatments are used on the liver transplant waiting list as neoadjuvant (or 
bridging) therapy, with the intent to reduce tumor growth and prevent dropout from the list, 
as well as improve outcome after transplantation (11, 12).  The current UK criteria recom-
mend that locoregional therapies are considered for all transplant list patients who have 
HCC. They are also used to down-stage tumors that currently fall outside Milan criteria 
(UNOS T3 or higher), with the aim of enabling listing for transplantation.   This also allows 
time to assess the tumor response, to gauge the biological behavior of the tumor and iden-
tify those patients at greater risk of tumor progression.  Duvoux et al found that patients 
moving from the high-risk group for tumor recurrence, according to the AFP-model, to the 
low-risk group on re-assessment after down-staging had the same risk of recurrence as 
those patients initially classified in the low-risk group (8). 
This use has been the subject of much debate, and the European Association for the 
Study of the Liver (EASL)/ European Organization for Research and Treatment of Cancer 
(EORTC) 2012 Clinical Practice Guideline (13) stated that down-staging for HCC beyond 
conventional criteria is not recommended and should be explored in the context of pro-
spective studies.  The Milan criteria for suitability for transplantation are well validated and 
widely used, and there is concern that increasing access to transplantation out-with these 
criteria could result in increasing rates of post-transplant HCC recurrence, and potentially 
represent poor use of a limited pool of donor organs.  However, down staging has been of 
great interest recently and identified as a priority for research at consensus meetings.  
(14) (15).  The International Consensus Conference on liver transplantation for HCC re-
ported that liver transplantation after down-staging should aim to achieve a 5 year survival 
rate comparable to those who initially fall within criteria for transplantation and that, based 
on existing evidence, no recommendation can be made for preferring a specific locore-
gional therapy for down-staging over others (16).  It is recognized that well-designed trials 
are needed to determine which patients would benefit from down staging. 
Tumor characteristics associated with progression include vascular invasion and poor dif-
ferentiation.  Since microvascular invasion and tumor grade can only be reliably deter-
mined by assessing the explant, surrogate markers of more aggressive tumors have been 
used, including tumor size and number (17) (18).  However, tumor size and number are 
not always accurate in predicting the behavior of the tumor, and bio-markers, including al-
pha-fetoprotein and des-gamma-carboxyprothrombin [DCP]), are also used to aid in pre-
dicting tumor aggressiveness.  These both correlate with post- treatment prognoses (19) 
(20, 21) (22, 23).  It has been suggested that the biological aggressiveness of the tumor 
may also be determined by response to locoregional therapies over a specified period (24) 
(25) (26) (27).  
Types of locoregional therapy 
TAE involves transarterial embolization with particles, including gelatin sponge particles 
(gel foam), polyvinyl alcohol, microspheres or drug eluting beads.  The occlusion of the ar-
terial supply results in tumor hypoxia and necrosis.   
TACE is the technique of infusing chemotherapy before embolization of particles.  TACE 
has been used in the majority of published studies and often several sessions of TACE are 
needed for down staging.  TACE is not a standardized procedure - studies vary in protocol 
in terms of the embolic and chemotherapeutic agents used, different particle size in embo-
lization, different arterial selectivity and variable surveillance protocols, time between ses-
sions and indication for repeating therapy.  Chemotherapeutic agents used include doxo-
rubicin, cisplatin, mitomycin C and 5-fluorouracil.  Embolization can be lobar, segmental or 
subsegmental.  TACE should be applied no more than 3–4 times per year, since shorter 
intervals can cause decompensation of liver disease. Super-selective TACE is more effec-
tive at inducing tumor necrosis and minimizes the ischemic insult to the remainder of the 
liver. It therefore may be employed if liver synthetic function is borderline (28) (13). Alt-
hough TACE is widely used, there is considerable heterogeneity in the studies that have 
used it (29). TACE is no better than TAE according to existing evidence (30). 
 Embolization with drug-eluting beads allows a steady local drug administration, however 
DEB-TACE was not more effective than conventional TACE in terms of tumor response in 
a randomized controlled trial. Its benefit though, is in limiting systemic exposure to the tox-
ic effects of chemotherapeutic agents, and has been shown to significantly reduce the in-
cidence of hepatitis and alopecia (31) (32-35). A phase II/III trial of 3-weekly cisplatin-
based sequential TACE showed a higher response rate than TAE alone but without a sur-
vival benefit (36).  
 TACI is a variant of TACE that is not at present widely-used.  TACI delivers high concen-
trations of chemotherapeutic drugs in a super-selective manner, without solid particle em-
bolization.  This affords it a better safety profile and can be used in patients with more ad-
vanced liver disease without the same risks of decompensation (37). 
HCC is radiosensitive and radio labelled particles delivered to the tumor transarterially lim-
its exposure to the surrounding liver and allows higher dose intensity.  Transarterial radio-
embolization (TARE) with Iodine-131 or Yttrium-90 glass beads has shown effectiveness 
in several studies, and is particularly useful in patients with portal vein thrombosis and no 
TACE option (38) (39) (40) (41) (42). 
Percutaneous techniques are effective in treating smaller lesions and can be curative 
when used for patients with early stage disease who are unsuitable for resection or trans-
plantation.  Tumor cells are damaged by thermal techniques (radiofrequency, microwave, 
laser) or injection of alcohol or acetic acid (43). PEI is inferior to RFA in treating tumors 
greater than 2cm in size (44) but equally  effective for tumors less than 2cm, with a low 
rate of adverse effects (45) (46). It may also be used in cases where RFA is not technically 
feasible. It is performed under ultrasound guidance and requires several sessions of 
treatment.  RFA is equally effective in lesions less than 2cm but with the need for fewer 
sessions. (47) (48) (49). RFA is more expensive than PEI and has a higher rate of adverse 
effects.  Both carry the risk of tumor seeding.  
A recent Cochrane meta-analysis on treatment of early or very-early HCC (BCLC stage A) 
concluded that mortality rate was higher for percutaneous acetic acid injection (hazard ra-
tio 1.77, 95% CI 1.12 to 2.79; 125 participants; 1 trial) and percutaneous alcohol injection 
(hazard ratio 1.49, 95% CI 1.18 to 1.88; 882 participants; 5 trials; I2 = 57%) compared with 
RFA for patients not eligible for liver resection. (50).  
Inclusion and exclusion criteria for downstaging 
There is no clear upper limit in terms of tumor size or number for eligibility for down-
staging.  The University of California, San Francisco protocol uses upper limits of one tu-
mor ≤8 cm, two or three tumors each ≤5 cm and the sum of the maximal tumor diameters 
≤8 cm, and four or five tumors each ≤3 cm and the sum of the maximal tumor diameters 
≤8 cm (51).  
A US national HCC conference proposed eligibility criteria that were a modification of the 
UCSF criteria: one tumor <8 cm, two or three tumors each <5 cm and the sum of the max-
imal tumor diameters <8 cm, and excluding four or five tumors (15).  Macroscopic vascular 
invasion or metastasis and poor liver function are usually exclusion criteria.  Tumor rupture 
and an AFP >10,000 IU/mL are absolute contraindications to transplantation.  The same 
conference proposed that transplantation should not be performed in those with AFP 
>1,000 ng/mL unless it decreases to <500 ng/mL with LDT (15). 
The International Consensus Conference on liver transplantation for HCC produced the 
recommendation that criteria for successful downstaging should include tumor size and 
number of viable tumors, noting that there is currently no well-defined upper limit for size 
and number of lesions as eligibility criteria for downstaging, although vascular invasion and 
extrahepatic disease are contraindications.  AFP levels before and after downstaging may 
add additional information, although there is no agreement on a threshold (16). 
Assessment of response and definitions of down-staging success or failure 
Response to locoregional therapies should be assessed by the modified Response Evalu-
ation Criteria in Solid Tumors (mRECIST), which assesses both change in tumor volume 
and in arterial enhancement.  The tumor dimensions are assessed by CT or MRI and the 
maximum size of only viable tumors is taken into account (24).   The EASL criteria also 
assess only viable tumor: the estimation of the reduction in viable tumor volume re cogni-
seed by non-enhanced areas by spiral CT (52).  The World Health Organization also sets 
criteria for down-staging success, which, like the mRECIST criteria, are based on the en-
tire lesion and not just the viable areas (50% reduction of the product of the perpendicular 
diameters of largest lesion).  The new dimensions of the tumor(s) are classified according 
to the UNOS TNM staging to assess whether down staging to within listing criteria has oc-
curred.  The definition of down staging is usually to within Milan criteria. 
Failure of LDT can be represented by metastasis and vascular invasion, and progression 
to beyond eligibility criteria for downstaging.  If tumor progression occurs but the active 
tumor burden remains within down-staging entry criteria, transplantation should be sus-
pended and repeat LDT should be undertaken until the endpoint of down-staging is 
achieved for the patients to be eligible again for transplantation (53). 
To address the heterogeneity of reporting of trials into locoregional therapy for HCC, 
Parikh proposed minimum criteria reporting for future studies in this area (54).  Yao pro-
posed a standardized downstaging protocol, including eligibility criteria and criteria for suc-
cessful downstaging or downstaging failure  (55). 
 
Risks of treatment  
The disadvantages of these treatments include potential risks related to their delivery.  
Post embolization syndrome is the most common adverse effect of TACE/TAE: a self-
limiting illness up to 48 hours post-procedure characterized by abdominal pain, fever and 
elevation of liver enzymes, observed in 60% of patients (56).  Side effects of TACE also 
include symptoms related to the chemotherapy: nausea, vomiting, marrow suppression, 
renal dysfunction (43).  Other TAE and TACE-induced adverse events include bile duct 
damage, liver abscess in necrotic tumor, ischemic cholecystitis and decompensation of 
cirrhosis with ascites, worsening of synthetic function, and potentially death (9).  The risk 
of decompensation is dependent on liver function pre-procedure and therefore patient se-
lection in studies of LDT has a significant effect on reported adverse outcomes.  In the 
presence of ascites, TACE-associated liver failure occurred in 17% and the mortality rate 
was high at one year (57).  Since the protocol for TAE/TACE varies by center, decisions 
about arterial selectivity for embolization will also affect outcome.  A systematic review re-
ported a median treatment related mortality of 2.4% in 37 trials including 2878 patients 
(35). 
Tumor seeding along the needle track may occur with percutaneous therapies.  The risk of 
adverse effects with RFA is up to 10%, including pleural effusion and  peritoneal bleeding, 
and procedure-related mortality is 0-0.3%  (58) (59). 
The most common treatment side effects of TARE were fatigue and transient nonspecific 
flu-like symptoms lasting 7–10 days, observed in 60% of patients.    
Finally, the ultimate potential harm with down staging is that of increasing post-transplant 
HCC recurrence, which may represent poor use of a limited pool of donor organs. 
 
Existing evidence of downstaging protocols 
It has been a challenge to make a judgement on outcomes in down staging therapy be-
cause of reported differences in treatment protocol and variability in survival data report-
ing.  The majority of studies have been single-center, with small cohorts.  A summary of 
the results of 14 studies discussed below is found in Table 3.  
A prospective study by Yao et al, San Francisco, California (51) compared 118 patients 
who underwent down staging to within T2 criteria.  Patients were consecutively enrolled in 
the down staging protocol from March 2002 to January 2012.  Eligibility criteria were tu-
mors beyond Milan criteria and up to 8 cm as follows: either a single tumor of ≤8cm, two to 
three tumors at least one >3 and ≤5cm and total diameter ≤8cm, four to five lesions each 
≤3cm and total diameter ≤8cm.    Modalities used were TACE (doxorubicin, cisplatin and 
mitomycin C), RFA, PEI and resection. Patients had CT or MRI one month after each LDT 
and a minimum of three monthly.  There was a minimum observation period of 3 months 
between LDT and listing for transplantation. Data for the control group of 488 patients 
meeting T2 criteria without requiring down staging were collected retrospectively. 
Downstaging, as defined by reaching Milan criteria, was successful in 77 (65.3%) patients, 
and 64 (54.2%) were eventually transplanted.  Post-transplant 5-year survival was 78% 
and intention to treat survival was 56%, compared to 63% in the group who initially met T2 
listing criteria (p=NS).  HCC recurrence was 7.5% (5 patients). Factors predicting dropout 
in the downstaging group included pretreatment alpha-fetoprotein >1,000 ng/mL (multivar-
iate hazard ratio [HR]: 2.42) and Child’s B versus Child’s A cirrhosis (multivariate HR: 
2.19).  Downstaging failed in 41 patients (34.7%) - because of tumor progression in 33, 
due to death without transplantation in 5 and for other reasons in 3.  The cumulative drop-
out rate was higher in this group than the control group. There were three deaths due to 
decompensation after LDT (treatment-related mortality 2.5%). This study’s strengths were 
its prospective nature, relatively large sample size, median 3.8 years post-transplant fol-
low-up and the control group of patients meeting Milan criteria, allowing comparison.  It al-
so reported eligibility and exclusion criteria and gave full details of the UCS downstaging 
protocol.  Explants were also analyzed and showed a low rate of unfavorable histological 
tumor characteristics, supporting the role of down staging to select more favorable tumor 
biology.   
In a prospective study by Ravaioli et al, from Italy (60), 48 patients had attempted down-
staging.  Patients were included from January 2003 to January 2006.  Eligibility criteria 
were HCC beyond Milan as follows: 1 lesion ≤6 cm, 2 lesions ≤5 cm, 3–5 lesions ≤4 cm 
and total diameter ≤12 cm (“Bologna criteria”).  Those with AFP level >400ng/ml were ex-
cluded.  Although the initial protocol included single nodules up to 8cm, the cohort did not 
in the end include any patient with a single nodule >6cm.  14.6% of patients in the down-
staged group met the UCSF criteria for transplantation. The modalities used were TACE, 
RFA, PEI, or resection used alone or in combination.  A minimum observation period of 3 
months was used between downstaging and listing.  Successful downstaging to within Mi-
lan criteria occurred in 33 (69%) patients and 32 (67%) underwent transplantation.  3-year 
disease-free survival was 71%, comparable to the cohort initially meeting Milan criteria 
(n=129), and 3-year intention to treat survival was 56.3% (62.8% in the Milan group).   
Tumor recurrence developed in 6 patients (18.8%; compared to 13.8% of those initially 
within criteria).  Treatment-related morbidity or mortality after LDT was not reported. 5 out 
of 48 (10.4%) cases did not complete the protocol, mainly due to tumor progression, which 
also resulted in removal from the waiting list in all cases. The number of cases excluded 
for tumor progression before transplantation was significantly higher in the down-staging 
group: 13 (27.1%) versus 15 cases (11.6%), (p < 0.05), despite a comparable waiting time 
before dropout (371 versus 290 days). The rate of deaths on the list due to decompensa-
tion was not statistically different (9% vs. 4%). This study had a smaller cohort of patients 
and shorter follow-up but its strengths were its prospective study design, clearly stated in-
clusion criteria and inclusion of a comparison group within Milan criteria.   
In a prospective study by Millonig from Austria, (61) 33 patients with HCC beyond Milan 
but within UCSF criteria had attempted down-staging with TACE using epirubicin and lip-
iodol. 30 patients were transplanted (transplantation rate 91%). Response was assessed 
by RECIST criteria and 85% had either partial or complete response.  6 patients with com-
plete response were transplanted and had a 5-yr survival of 67%, 22 patients with partial 
response were transplanted, and had a 5-year survival of 64%.  Two had stable or pro-
gressive disease and 5-year survival was 25%.  In this study, TACE did not confer a sur-
vival benefit in the group exceeding Milan criteria, even if it led to tumor regression pre-
transplantation.   Conversely, response to LDT did confer a survival benefit to the patients 
within Milan criteria on the waiting list for transplantation. In contrast to the previous stud-
ies, the authors found that Milan stage significantly affected survival and recurrence rates 
post-transplantation, when compared to UCSF-expanded criteria, and was a better predic-
tor of poorer outcomes than response to TACE.  Recurrence rate was 25% (7 patients) 
(recurrence 7.6% in the Milan group).  Treatment-related mortality is not reported specifi-
cally but side effects of TACE in this study were pain, fever, nausea, and inguinal hema-
toma. Two patients developed a hepatic abscess after TACE, which required antibiotic 
treatment alone in 1 patient and required drainage plus antibiotic treatment in the other.  
In a prospective study by Graziadei et al.,
 
Austria, (62) 15 patients with HCC beyond Milan 
criteria, with no upper limits in tumor size or number, underwent TACE therapy between 
January 1997 and December 2001.  Epirubicin and lipiodol were used.  Response was de-
fined as a 50% reduction in tumorr size and this was achieved in 67%.  Patients who re-
sponded to the first TACE session were listed for transplantation and TACE was repeated 
6-8 weekly until complete response was achieved or organ became available.  10 (67%) 
were transplanted and the 4-year post-transplant survival was 41%, 5-year intention-to-
treat survival was 31%.  Recurrence developed in 30% (3 patients). TACE was generally 
well-tolerated but one patient in the down staging group developed a liver abscess, requir-
ing antibiotic therapy, and one patient in the Milan group required surgical drainage for he-
patic abscess.   This study found that downstaged patients had significantly worse survival 
and recurrence outcomes than the group within Milan criteria, however the numbers stud-
ied were small which may limit the conclusions that can be drawn.  
A retrospective cohort study by De Luna et al, Stanford, California (63) included 27 pa-
tients who had attempted down-staging with transarterial chemoinfusion (TACI) between 
January 1995 and March 2008.  The eligibility criteria were tumors beyond Milan criteria 
but there were no upper limits in tumor number and size.  They were compared to a group 
of 95 patients meeting Milan criteria.  The chemotherapeutic agent consisted of an emul-
sion of Ethiodol, cisplatin and doxorubicin dissolved in the contrast medium.   After infu-
sion, if there was still arterial feeding of the tumor, gelfoam was introduced via the cathe-
ter.  If there was still evidence of viable tumor at a 3 month follow up CT, another session 
of TACI was offered.   Downstaging to within Milan criteria was achieved in 17 patients 
(63%). Fifteen patients (55.6%) were transplanted and the three-year post-transplant sur-
vival of the group of down-staged patients was 78.8%. This was not a statistically signifi-
cant difference to the 82.4% survival of those meeting Milan criteria. HCC recurrence was 
observed in just one patient (recurrence rate 7%). The rate of serious complications was 
5.6%. Symptoms included nausea, vomiting, fever, variceal bleeding and encephalopathy. 
One patient required surgery for a right groin hematoma and pseudoaneurysm. The main 
drawbacks of this study were its retrospective design and small cohort size from a single 
centre.  
In a single-centre retrospective cohort study by Green et al, Colorado, (64) 22 patients had 
down-staging with DEB TACE (doxorubicin-eluting beads).  Eligibility criteria were beyond 
Milan, UNOS T3; no upper size limits for up to 3 lesions.  Patients were included between 
September 2008 and December 2011. 17 out of 22 (77%) were successfully down-staged, 
as assessed by mRECIST criteria and 7 (32%) were transplanted.  HCC recurrence was 
29% (2 patients).  Treatment related mortality or morbidity was not reported.  This study 
lacked longer-term post-transplantation follow-up data on mortality and recurrence (medi-
an post-transplantation follow-up 26.1 months).  
 
In a retrospective cohort study by Barakat et al.,
 
Houston, Texas, (65) 32 patients under-
went down-staging with TACE, TARE and RFA.  They were included from June 2003 to 
April 2006. Inclusion criteria were beyond Milan and UCSF criteria, with no upper limit in 
size or number of lesions. The study protocol was for patients to receive TACE with Ethio-
dol and doxorubicin, and this was then followed by either RFA or TARE with radioactive 
Yttrium-90 resin microspheres.  The type of LDT used and number of sessions was indi-
vidual specific, but in general TACE followed by RFA was preferred when there were fewer 
and smaller lesions, and TACE followed by TARE was used when HCC was multifocal or 
larger than 6cm, or as third line after the other therapies. RFA was percutaneous, laparo-
scopic or open.  For those with preserved liver function, resection was performed.  The 
majority of patients received multimodal treatment. Additional sessions of LDT were of-
fered if there were signs of progression or recurrence during surveillance.  Down-staging 
success, to within UNOS T2 criteria, was achieved in 18 patients (56%) and 14 (44%) 
were transplanted.  2-year survival was 75% and HCC recurrence was 14% (2 patients, at 
median 35 months follow-up). 55.5% of those successfully down-staged had HCCs outside 
the proposed UCSF criteria for downstaging. Four patients (28.5%) with infiltrative tumors 
died of progressive liver failure during LDT and the authors suggested caution with ag-
gressive treatments for these types of tumors.  Treatment-related morbidity and mortality 
were not reported for the whole group.  
In a retrospective cohort study by Jang et al, Seoul, Korea, (66) 386 patients with pre-
served hepatic synthetic function had attempted down-staging with TACE with no upper 
limits in tumor number and size for tumors beyond the Milan criteria. Patients were con-
secutively enrolled between June 2000 and December 2007.  The treatment was lipiodol 
plus epirubicin and/or cisplatin, without gelfoam embolization and was repeated at one to 
two monthly intervals as needed, until complete necrosis of all lesions was seen.  160 
(41.5%) were successfully down-staged to within Milan criteria and 37 (9.6%) were trans-
planted.  5-year survival was 54.6% and 11 (29.7%) had recurrent HCC. This study, like 
others, suggested that there is an upper limit in tumor size, above which, no benefit can be 
gained from down staging before liver transplantation. In this study, tumor size >7 cm, in-
complete necrosis after TACE and AFP >100 ng ⁄ mL were predictors of poorer outcome.  
As there is a scarcity of deceased donor livers in Korea, living donor transplantation was 
utilized in the majority.  This meant that most recipients were transplanted soon after suc-
cessful down-staging, without an observation period, and that the results may not be appli-
cable to deceased donor transplantation.  Although the down staging cohort was large, the 
number of patients transplanted was small, reducing the power of the conclusions drawn 
from follow-up analysis. 
In a retrospective cohort study by Lewandowski et al., Chicago, Illinois, (67) down-staging 
was attempted in 86 patients between January 1, 2000 and December 31, 2008.   Patients 
had UNOS T3 HCC and no upper size limits for up to 3 lesions.  TACE was used in 43 pa-
tients and TARE was used in another 43 patients with HCC beyond Milan criteria.  This 
was not randomized - TARE was used in those in whom TACE was unlikely to be tolerated 
(more elderly patients).   TACE delivered mitamycin, adriamycin and cisplatin with lipiodol, 
followed by embolization particles.  TARE was performed using Yttrium-90 microspheres.  
Patients were imaged one month after treatment, and on 3 monthly intervals thereafter.  
Response was assessed using World Health Organization criteria (50% decrease in cross-
sectional diameter of target lesions from baseline) and EASL criteria (50% necro-
sis/avascularity in target lesions from baseline).  Eight patients in the TACE cohort did not 
have follow-up imaging (reasons were early post treatment transplant, death or lost to fol-
low up) and so down-staging outcomes are based on 35 patients.  EASL complete re-
sponse rates were 6 (17%) in the TACE group and 20 (47%) in the TARE group.  58% 
(25/43) in the TARE group were successfully down-staged to T2 and 31% (11/35) in the 
TACE group achieved down-staging. 26% (11/43) TACE and 21% (9/43) TARE-Y90 pa-
tients were transplanted. 3-year survival after transplantation or resection was 19% for the 
TACE cohort and 45% for TARE patients.  Intention-to-treat survival was 19% in the TACE 
group and 59% in the TARE group.  HCC recurred in 18% (2/11) of the TACE patients and 
22% (2/9) of the TARE-Y90 patients. Post-embolization syndrome was observed in 60% of 
patients in the TACE group.  Transient flu-like symptoms lasting 7–10 days were observed 
in 60% of patients in the TARE group. The study was retrospective and single-center, with 
non-randomized cohort arms, which could have left it open to bias.  In addition, the imag-
ing assessment of downstaging differed from the recommended mRECIST or EASL crite-
ria: the entire lesion was measured rather than only the enhancing viable parts (WHO cri-
teria). 
In a retrospective cohort study by Chapman et al, 
 
St. Louis, Missouri, (68) 76 patients with 
HCC between 1999 to 2006 had attempted downstaging with TACE.  Eligibility criteria 
were tumors beyond Milan, with no upper limits in lesion size and number.  The definition 
of response was based on RECIST criteria and this was achieved in 23.7% (18/76). 17 
(22.4%) were transplanted and 5-year survival was 94.1%.  HCC recurrence was 6% (1 
patient). Three patients died from the whole cohort of 136 treated with TACE (30-day mor-
tality 2.2%). Deaths were due to liver failure or tumor lysis syndrome. One patient required 
percutaneous drainage of liver abscess post-TACE. 
In a retrospective study of consecutive patients by Otto et al.,
 
Germany, (25) between May 
1998 and May 2005, 62 patients with HCC beyond Milan criteria, with no limits in tumor 
size or number, underwent attempted downstaging with TACE, which was performed in 6-
weekly intervals until transplantation. Mitomycin and lipiodol were used.  The aim of the 
study was to transplant patients who responded to TACE even if their tumor initially and 
after downstaging exceeded the listing criteria, in order to study the oncological result of 
treatment. The RECIST criteria were used to assess response and 34 (55%) had a partial 
response to TACE and were listed. TACE continued on the waiting list and 27 (44%) pa-
tients underwent transplantation.  Recurrence free 5-year survival was 74.5%.  Hepatic 
decompensation occurred in 5 patients during downstaging (8%). In this study, freedom 
from recurrence was associated with response to TACE but was not related to Milan 
stage.  The authors therefore suggested that response to TACE is a better criterion for se-
lection for transplantation than tumor number and size as it is more predictive of recur-
rence.   
In a retrospective cohort study by Majno et al.,
 
France, (69) between January 1985 and 
December 1995, 35 patients with tumor size >3cm, of any number, underwent LDT with 
TACE prior to transplantation.  Lipiodol with doxorubicin or cisplatin was used, with gelatin 
sponge powder or pellets embodied afterwards.  Response was defined by WHO criteria 
and this was achieved in 19 (54%).  All 35 were transplanted and 5-year disease-free sur-
vival was 71% in those who had achieved down-staging (n=19) compared to 29% without 
response to TACE (n=16).  TACE was generally well-tolerated with no increased rate of 
liver failure post-operatively, however there was one case of severe hepatocellular failure 
in whom TACE had been performed despite a pre-existing surgical shunt.  This patient 
was rescued by emergency transplantation.  This study demonstrated that those tumors 
>3cm which respond to TACE have similar post-transplantation recurrence as smaller le-
sions.  
A retrospective study by Pracht et al (42) treated patients with lobar HCC and ipsilateral 
portal vein thrombosis with Yttrium-90 glass microspheres with intention to downstage to 
resection or transplantation.  18 patients were included from January 2007 to December 
2010 and radiological assessment of response was by EASL criteria, at 3 and 6 months.    
All patients had good liver synthetic function and performance status.  Mean follow-up was 
13.0 months (range 2.2–50.6).  Two patients (11%) were down-staged to within transplan-
tation criteria and a further 2 to resection. One patient was transplanted (5.6%) and had an 
overall survival of 50.6 months.  Overall survival for the whole group at 1 year was 70.3%. 
Seven patients (38.9%) developed transient liver dysfunction, 6 patients decompensated 
with ascites and 1 hepatic encephalopathy. No deaths were attributed to the treatment.  
The authors concluded that TARE was an effective therapy for down staging HCC with 
portal vein thrombosis.  The main limitations of this study were its retrospective design, 
small cohort and short follow-up time, which may limit the conclusions that can be drawn.  
 
In a retrospective study by Bova et al, (70) 48 patients with HCC beyond Milan, without 
tumor thrombus or metastases, underwent TAE, TACE or TOCE (transarterial oily che-
moembolization) between January 2004 and December 2010.  Epirubicin and/or lipiodol 
and gelfoam were used.  19 (40%) were successfully down-staged, by mRECIST criteria.  
AFP level <100 ng/mL and 3-year calculated survival probability using the Metroticket cal-
culator were independent predictors of successful downstaging (p <0.023 and p < 0.049 
respectively). In the downstaged group, the 5-year survival rate was 60 %.  9 (19%) un-
derwent OLT and recurrence rate was 11% (1 patient) at median follow up of 40 months. 
No major complications were observed after the intra-arterial therapies. Morbidity included 
abdominal pain, nausea and transient fever.  
A systematic review of thirteen trials (950 patients) by Parikh et al (54) showed the overall 
success rate of down staging therapy to be 48% but with a recurrence rate of 16%.  Stud-
ies that included patients with portal vein thrombosis had the lowest success rates and ex-
cluding these brought the pooled success rate up to 54%.  There was also a significantly 
improved success rate for those studies with a prospectively designed study protocol, 
compared to retrospective studies.  There was no clear difference in efficacy between 
TACE and TARE.  The highest success rates came from studies with multimodal LDT 
treatments, all of which included a proportion of patients undergoing liver resection for 
downstaging.   Modality did not have an effect on recurrence rate.  The review noted vari-
ability in reporting of post transplantation survival data, and so a pooled analysis could not 
be made.  The majority of studies reported over 90% survival at 1 year but 4- or 5-year 
survival rates varied from 70% to over 90%. There was inconsistent reporting of inclusion 
criteria and heterogeneity in baseline tumor burden, downstaging protocol, waiting time 
and assessment of response.  Only two studies included a mandatory waiting period be-
fore listing for transplantation. 
Conclusions 
Drawing clear conclusions about the use of locoregional therapies to down-stage hepato-
cellular carcinoma is made difficult by the heterogeneity of published studies so far.  There 
are variations in inclusion criteria - tumor burden, treatment protocols, and study designs - 
prospective or retrospective; definitions of response and inclusion or not of mandatory 
waiting time after between down staging and transplantation.  The protocol, modality and 
delivery technique used is also variable.  Within these limitations, pooled analyses have 
suggested success in down staging in about half (48%) of patients treated, but with higher 
recurrence rates than patients initially within transplantation criteria (16%) (54).  Studies 
with strict inclusion criteria and mandatory waiting time before transplantation reported bet-
ter outcomes in terms of success of down staging and recurrence rate, with survival equiv-
alent to patients who did not require down staging (5-year survival 78%) (51).  This would 
satisfy the requirement set out by the international consensus group (16).  Treatment-
related morbidity, where reported, was generally mild.  Treatment-related mortality was not 
reported in the majority of studies but, where reported, was around 2.5%. 
 
It is likely that, in carefully selected patients, there is a role for down staging to provide the 
chance of transplantation and cure, with acceptable outcomes.  Further multi center, well-
designed studies are needed to clarify who will benefit.  There should be criteria stated 
within transplantation programs, defining eligibility for down staging and decisions regard-
ing each case should be discussed by the multidisciplinary team, involving hepatologists, 
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